{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.3","upperLimit":"10.6","value":"6.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Time to treatment failure is defined to be the time from the date of registration to the date at which the patient is removed from treatment due to progression, toxicity, or refusal. If the patient is considered to have had a major treatment violation or is taken off study as a non-protocol failure, the patient will be censored on the date they are removed from treatment. Time to treatment failure will be analyzed using Kaplan-Meier methods.","dispersionType":"95% Confidence Interval","groups":[{"description":"Group 1 (6/6 UGT1A1 genotype):\\> Patients receive 150 mg/m\\^2 irinotecan hydrochloride IV over 90 minutes and 100 mg/m\\^2 oxaliplatin IV over 2 hours on day 1. Patients also receive 1600 mg/m\\^2/day capecitabine PO BID on days 2-15\\> \\> Group 2 (6/7 UGT1A1 genotype):\\> Patients receive 150 mg/m\\^2 irinotecan hydrochloride IV over 90 minutes and 85 mg/m\\^2 oxaliplatin IV over 2 hours on day 1. Patients also receive 400 mg/m\\^2/day capecitabine PO BID on days 2-15.\\>\n\n\\> Group 3 (7/7 UGT1A1 genotype):\\> Patients receive 75 mg/m\\^2 irinotecan hydrochloride IV over 90 minutes and 85 mg/m\\^2 oxaliplatin IV over 2 hours on day 1. Patients also receive 400 mg/m\\^2/day capecitabine PO BID on days 2-15","id":"OG000","title":"All Patients (6/6, 6/7, 7/7 UGT1A1 Genotype)"}],"paramType":"MEDIAN","populationDescription":"One patient was later found to be a major treatment violation during cycle 1 and was not included in this analysis. All the other 32 patients were analyzed together for this endpoint.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Time to Treatment Failure","type":"SECONDARY","unitOfMeasure":"months"}